N-methyl-D-aspartate receptor antibody antibody-mediated neurological disease: results of a UK-based surveillance study in children

Sukhvir Wright,1,2 Yael Hacohen,1 Leslie Jacobson,1 Shakti Agrawal,2 Rajat Gupta,2 Sunny Philip,2 Martin Smith,2 Ming Lim,1,3 Evangeline Wassmer,1 Angela Vincent1

ABSTRACT

Objective N-methyl-D-aspartate receptor antibody (NMDAR-Ab) encephalitis is a well-recognised clinically-immunological syndrome that presents with neuropsychiatric symptoms, cognitive decline, movement disorder and seizures. This study reports the clinical features, management and neurological outcomes of paediatric NMDAR-Ab-mediated neurological disease in the UK.

Design A prospective surveillance study. Children with NMDAR-Ab-mediated neurological diseases were voluntarily reported to the British Neurological Surveillance Unit (BPNSU) from November 2010 to December 2011. Initial and follow-up questionnaires were sent out to physicians.

Results Thirty-one children fulfilled the criteria for the study. Eight presented during the study period giving an incidence of 0.85 per million children per year (95% CI 0.64 to 1.06); 23 cases were historical. Behavioural change and neuropsychiatric features were present in 90% of patients, and seizures and movement disorders both in 67%. Typical NMDAR-Ab encephalitis was reported in 24 children and partial phenotype without encephalopathy in seven, including predominantly psychiatric (four) and movement disorder (three). All patients received steroids, 22 (71%) received intravenous immunoglobulin, 9 (29%) received plasma exchange, and 10 (32%) received second-line immunotherapy. Of the 23 patients who were diagnosed early, 18 (78%) made a full recovery compared with only 1 of 8 (13%) of the late diagnosed patients (p=0.002, Fisher’s exact test). Seven patients relapsed, with four needing additional second-line immunotherapy.

Conclusions Paediatric NMDAR-Ab-mediated neurological disease appears to be similar to adult NMDAR-Ab encephalitis, but some presented with a partial phenotype. Early treatment was associated with a quick and often full recovery.

INTRODUCTION

N-methyl-D-aspartate receptor antibody (NMDAR-Ab) encephalitis is the most widely studied of the recently described autoimmune encephalitis.1,2 Primarily affecting young adults and children, the typical presentation is with subacute onset behavioural change, neuropsychiatric features and seizures, usually progressing to movement disorder, hyperventilation, reduced consciousness and autonomic instability.3 The association with an underlying ovarian teratoma4 depends on age and sex, and is most frequent (up to 50%) in young women.5,6 The paediatric presentation has been described as more ‘neurological’ than the more psychiatric presentation in adults.6,7 Patients are treated with tumour resection if required, first-line immunotherapy (intravenous and/or oral steroids, intravenous immunoglobulin, and/or plasma exchange (PLEX)) and second-line immunotherapy (cyclophosphamide or rituximab) if indicated.8 More than 75% of all patients have a substantial recovery, with early recognition and treatment predictive of a good outcome.3 This information, however, has been largely gathered from patient cohorts, mainly comprising retrospective data,6,7 and as yet, no incidence rates and outcomes have been reported from population-based prospective cohorts. Here, we report a prospective surveillance study in the UK to ascertain incidence, clinical, investigative features and outcomes of childhood (age <18 years) NMDAR-Ab encephalitis.

METHOD

Study design

A UK-wide prospective surveillance study of NMDAR-Ab encephalitis in children (1–17 years 11 months), in conjunction with the British Paediatric Neurology Surveillance Unit (BPNSU), recruited patients from November 2010 to December 2011.
2011 (13 months). Through a web-based portal (http://www.bpnusu.co.uk/), monthly notification emails were sent to all registered consultant paediatric neurologists during the study period. Clinicians replied to the email notifying any cases or confirming ‘nothing to report’. Upon receipt of a positive notification, the surveillance unit provided the investigating team with a BPNSU case number and clinician contact details.

**Case definition and identification**

The case definition for this study was ‘any child or young adult, who presents with new onset of acute behavioural change, seizures, dystonias or dyskinesias and with antibodies to the NR1 subunit of the NMDAR in the serum and/or CSF’. Clinicians were asked to report both new and previous cases. The study team contacted the clinician directly and sent two questionnaires: one at notification and one at 12 months (see online supplementary information). ‘Late diagnosis’ was defined as identification of NMDAR-Abs >6 months from disease presentation; 19 of these cases have been reported previously as part of a case series, cohort or as case reports. Treatment response was derived from the clinician responses in the questionnaire, and mRS (modified Rankin Scale) for children (appended to the follow-up questionnaire) was used to measure outcomes.

**Statistical analysis**

Descriptive statistics were used to summarise the key components of the dataset. Fisher’s exact test (two-tailed) was used to compare clinical details in GraphPad Prism V6.

**Approvals**

The study proposal was approved by the BPNSU executive committees. The study had approval from the UK Multicentre Research Ethics Committee and the Oxfordshire Regional Ethical Committee A (07/Q1604/28) with a substantial amendment (1) approved on 30 April 2010.

**RESULTS**

Over the study period (13 months), 1526 email responses were received from 171 clinicians reporting 35 known and 10 new cases. A review of the Oxford neuroimmunology database confirmed the positive NMDAR-Ab results. Three children with positive results were identified from the Oxford database and not reported to the BPNSU. Of the 35 completed questionnaires received, 31 cases from 13 different centres met the case study definition. Seven of these patients had been diagnosed late (over 6 months). Four patients were excluded; one was too old at the time of presentation (19 years old); the second patient was excluded as his NMDAR-Ab positivity was low and his serum immunoglobulin (Ig)G also bound to other antigens suggesting non-specificity, possibly due to previous intravenous immunoglobulin (IVIG) treatment causing raised serum IgG levels; two patients had an uncomplicated Tetalogy of Fallot history of autoimmune disease. Good premorbid health and development were seen in 28/31 (90%); two patients had an uncomplicated Tetralogy of Fallot repair in infancy and another patient had a XXX karyotype with developmental delay. There was no significant family history of autoimmune disease.

The clinical features are summarised for each patient in table 1A, B. Behavioural change and/or neuropsychiatric features were the initial presenting symptom in 90% (28/31). During the course of the disease, seizures and new onset movement disorders were both seen in 21/31 patients (68% in each case). Sleep dysfunction was reported in 16/31 (52%) and autonomic features were found in 12 (39%) cases, with cardiac abnormalities including one cardiac arrest, and hyperventilation requiring intensive care support in three cases. Individual patients exhibited myoclonus, neumyotonia or transient limb weakness. Partial phenotypes, predominant movement (n=3) or psychiatric features (n=4), were reported more frequently in boys (n=4) (4/8 boys vs 3/23 girls, p=0.05, Fisher’s exact test). The patients with partial

**Clinical features of all patients**

Good premorbid health and development were seen in 28/31 (90%); two patients had an uncomplicated Tetralogy of Fallot repair in infancy and another patient had a XXX karyotype with developmental delay. There was no significant family history of autoimmune disease.

![Figure 1](http://www.ons.gov.uk) Demographic data of UK patients with N-methyl-D-aspartate receptor-antibody encephalitis. Age of onset stratified to sex (A) showing an overall female predominance. Boys were more likely to present at over the age of 5 years (p=0.03, Fisher’s exact test). Ethnicity of the patients (B), 14 patients (45%) were non-Caucasian.
phenotypes had at least one additional symptom (behavioural change, movement disorder, psychiatric features or seizures) and were not monosymptomatic (table 1).

Paraclinical features of all patients
Cerebrospinal fluid (CSF) was abnormal with pleocytosis in 45% (13/29). Eight of 12 (67%) had intrathecal oligoclonal bands. Seven serum/CSF pairs were positive for NMDAR-Abs; two CSFs sent later during the disease course were negative. MRI scans were normal in 20/31 (65%), but high signal changes in cortical (frontal, frontoparietal, temporal, hippocampi), and subcortical areas (basal ganglia) were seen in 7/31 (23%). Electroencephalography (EEG) was encephalopathic in the majority (28/30; 93%). The finding of extreme delta brush was not reported. The EEG was normal in two of the cases with partial phenotypes (Cases 19 and 9). Three patients had a positive antistreptolysin O titre, one of whom was also positive for IgM Epstein–Barr virus antibodies. Other antibodies identified included antinuclear antibody and extractable nuclear antigen in one patient, antibasal ganglia antibodies and voltage-gated potassium channel-complex antibodies (661 pmol/L) in another.

Table 1 Predominant symptoms at presentation, and outcomes at final follow-up

(A)  
<table>
<thead>
<tr>
<th>Case number</th>
<th>Age: sex</th>
<th>Clinical features</th>
<th>Time to diagnosis/time to treatment response</th>
<th>Treatment group</th>
<th>Outcome/ΔmRS score*</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>14: F</td>
<td>BC, S, MD, Sp</td>
<td>6 months/2 days</td>
<td>A</td>
<td>Full recovery no sequelae(5)</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>BC, S, MD</td>
<td>9 months/90 days</td>
<td>D</td>
<td>Cognitive problems(3)</td>
</tr>
<tr>
<td>4</td>
<td>10: F</td>
<td>BC, S</td>
<td>&gt;1 year/no response</td>
<td>A</td>
<td>Cognitive problems(1)</td>
</tr>
<tr>
<td>16</td>
<td>6: M</td>
<td>BC, S, MD</td>
<td>&gt;1 year/7 days</td>
<td>A</td>
<td>Seizures, on treatment(4)</td>
</tr>
<tr>
<td>20</td>
<td>10: F</td>
<td>BC, S, MD</td>
<td>&gt;1 year/no response</td>
<td>A</td>
<td>Significant disability, relapse, leucoencephalopathy on MRI (0)</td>
</tr>
<tr>
<td>28</td>
<td>8: M</td>
<td>BC, S, MD</td>
<td>7 months/3 days</td>
<td>A</td>
<td>One encephalopathic relapse treated with steroids(2)</td>
</tr>
</tbody>
</table>

Partial phenotypes
<table>
<thead>
<tr>
<th>Case number</th>
<th>Age: sex</th>
<th>Clinical features</th>
<th>Time to diagnosis/time to treatment response</th>
<th>Treatment group</th>
<th>Outcome/ΔmRS score*</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>10: F</td>
<td>MD, Sp</td>
<td>&gt; 1 yr/28 days</td>
<td>A</td>
<td>Symptom recurrence when unwell (1)</td>
</tr>
</tbody>
</table>

(B)  
<table>
<thead>
<tr>
<th>Case number</th>
<th>Age: sex</th>
<th>Clinical features</th>
<th>Time to diagnosis/time to treatment response</th>
<th>Treatment group</th>
<th>Outcome/ΔmRS score†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>14: F</td>
<td>BC, S, MD</td>
<td>1 month/90 days</td>
<td>D</td>
<td>Full recovery no sequelae(3)</td>
</tr>
<tr>
<td>5</td>
<td>3: F</td>
<td>BC, S</td>
<td>1 week/7 days</td>
<td>A</td>
<td>Full recovery no sequelae(4)</td>
</tr>
<tr>
<td>6</td>
<td>5: F</td>
<td>BC, S, MD</td>
<td>1 month/14 days</td>
<td>C</td>
<td>Antibodies remain high, cognitive problems(3)</td>
</tr>
<tr>
<td>7</td>
<td>9: M</td>
<td>BC, S, MD, NMT</td>
<td>2 months/90 days</td>
<td>A</td>
<td>Full recovery no sequelae(5)</td>
</tr>
<tr>
<td>9</td>
<td>2: F</td>
<td>BC, S, MD, Sp</td>
<td>5 weeks/7 days</td>
<td>A</td>
<td>Full recovery no sequelae(4)</td>
</tr>
<tr>
<td>10</td>
<td>14: F</td>
<td>BC, S, MD</td>
<td>1 week/29 days</td>
<td>D</td>
<td>One relapse treated with IV/PO steroids and MMF, full eventual recovery no sequelae(5)</td>
</tr>
<tr>
<td>11</td>
<td>2: F</td>
<td>BC, S, MD</td>
<td>&lt;1 week/72 days</td>
<td>D</td>
<td>Full recovery no sequelae(4)</td>
</tr>
<tr>
<td>12</td>
<td>8: F</td>
<td>BC, S, MD</td>
<td>2 months/60 days</td>
<td>C</td>
<td>Full recovery no sequelae(3)</td>
</tr>
<tr>
<td>13</td>
<td>15: F</td>
<td>BC, S, MD, Sp</td>
<td>1 week/14 days</td>
<td>A</td>
<td>Lost to follow-up</td>
</tr>
<tr>
<td>14</td>
<td>13: F</td>
<td>BC, S, MD, NMT</td>
<td>1 week/14 days</td>
<td>A</td>
<td>Relapse at 1 year treated with AZT and MMF, full eventual recovery(2)</td>
</tr>
<tr>
<td>15</td>
<td>2: F</td>
<td>BC, S, MD</td>
<td>2 weeks/30 days</td>
<td>A</td>
<td>Ongoing seizures, cognitive problems, antibodies elevated(3)</td>
</tr>
<tr>
<td>17</td>
<td>4: F</td>
<td>BC, S, MD</td>
<td>2 weeks/30 days</td>
<td>A</td>
<td>Developmental arrest same as predisease stage, cognitive and behavioural problems (3)</td>
</tr>
<tr>
<td>22</td>
<td>17: F</td>
<td>BC, S, MD</td>
<td>3 weeks/3 days</td>
<td>B</td>
<td>Full recovery no sequelae(5)</td>
</tr>
<tr>
<td>24</td>
<td>14: F</td>
<td>BC, S, MD</td>
<td>1 month/1</td>
<td>A</td>
<td>Cognitive problems and seizures(2)</td>
</tr>
<tr>
<td>26</td>
<td>3: F</td>
<td>BC, S, MD</td>
<td>1 month/28 days</td>
<td>D</td>
<td>Full recovery no sequelae(1)</td>
</tr>
<tr>
<td>27</td>
<td>11: M</td>
<td>BC, MD</td>
<td>12 days/8 days</td>
<td>A</td>
<td>Full recovery no sequelae(5)</td>
</tr>
<tr>
<td>30</td>
<td>2: F</td>
<td>BC, MD</td>
<td>2 weeks/19 days</td>
<td>A</td>
<td>Cognitive and behavioural problems(2)</td>
</tr>
<tr>
<td>31</td>
<td>2: F</td>
<td>BC, MD</td>
<td>4 weeks/67 days</td>
<td>D</td>
<td>Full recovery no sequelae(5)</td>
</tr>
</tbody>
</table>

Partial phenotypes
<table>
<thead>
<tr>
<th>Case number</th>
<th>Age: sex</th>
<th>Clinical features</th>
<th>Time to diagnosis/time to treatment response</th>
<th>Treatment group</th>
<th>Outcome/ΔmRS score†</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>17: M</td>
<td>NPsych, BC, S</td>
<td>3 weeks/14 days</td>
<td>B</td>
<td>Full recovery no sequelae(4)</td>
</tr>
<tr>
<td>18</td>
<td>5: F</td>
<td>MD, S, Sp</td>
<td>&lt;1 week/7 days</td>
<td>A</td>
<td>Full recovery no sequelae(3)</td>
</tr>
<tr>
<td>21</td>
<td>12: M</td>
<td>MD, NPsych</td>
<td>8 weeks/7 days</td>
<td>A</td>
<td>Full recovery no sequelae(1)</td>
</tr>
<tr>
<td>23</td>
<td>16: M</td>
<td>NPsych, BC</td>
<td>1 month/7 days</td>
<td>C</td>
<td>Two relapses before MMF, none since started (1)</td>
</tr>
<tr>
<td>25</td>
<td>15: F</td>
<td>NPsych, BC</td>
<td>2 months/2 days</td>
<td>D</td>
<td>Relapse treated with steroids, cyclophosphamide and rituximab (4)</td>
</tr>
<tr>
<td>29</td>
<td>14: M</td>
<td>NPsych, BC</td>
<td>2 months/5 days</td>
<td>A</td>
<td>Relapse treated with PLEX and second-line immunotherapy; eventual full recovery (0)</td>
</tr>
</tbody>
</table>

(A) lists patients with late diagnosis; (B) lists patients diagnosed within 8 weeks from symptoms onset. Patients with partial phenotypes were defined based on a lack of encephalopathy as evaluated by clinician.

*Outcome at final follow-up. ΔmRS score from nadir to 12-month postpresentation.
†Denotes patient with ovarian teratoma.

AZT, azathioprine; BC, behavioural change; EPC, epilepsia partialis continua; IV/PO, intravenous/oral; MD, movement disorder; MMF, mycophenolate mofetil; NMT, myotonia; NPsych, neuropsychiatric; PLEX, plasma exchange; S, seizures; Sp, speech dysfunction.
Clinical response to initial therapy: speed and extent

All patients received steroids; 22 (71%) received IVIG, 9 (29%) received PLEX and 10 (32%) received second-line immunotherapy. Four treatment groups were identified within the whole cohort of 31 patients (figure 2A). The most frequently used (61%) were IVIG and steroids (Group A); PLEX was added to these in two patients (Group B). Three patients had IVIG, steroids, no PLEX, but second-line immunotherapy (Group C). Seven patients had steroids, IVIG, PLEX, and second-line immunotherapy (Group D). A total of 10 (32%) patients were treated with second-line or long-term immunotherapy using cyclophosphamide (n=3), rituximab (n=3) or both (n=3), with mycophenolate mofetil (MMF) initiated in one patient. No significant treatment complications/side effects were reported in any of the 31 patients. Eighteen of 31 (58%) patients showed a response to immunotherapy within 30 days, but in three patients, this took up to 90 days. Thirteen patients required intensive care support during their illness (13/31; 42%). The median length of patient stay in hospital was 60 days (range 10–365 days), and four (range 1 day–7 days) other health/medical professionals were needed during admission for each case (figure 3). There was no correlation between age of presentation and response to immunotherapy, and no relationship between initial response to immunotherapy and outcome at 12 months (table 1). However, 89% (8/9) patients who received PLEX during their initial treatment made a full eventual recovery compared with 47% receiving IVIG and steroids only (p=0.049, Fisher’s exact test), although this might have been confounded by additional second-line immunotherapies, as 7/9 of the patients had also received second-line immunotherapy.

Comparison of clinical response between early and late diagnosis groups

Late diagnosis (>6 months)

Seven patients were not tested for NMDAR-Abs until over 6 months from symptom onset (table 1A). Despite the delay in diagnosis, all had received steroids and/or IVIG, and one had MMF (Case 3). One child (Case 2), who responded to first-line immunotherapy, was found to have NMDAR-Abs 6 months after initial presentation, while asymptomatic and off treatment, and was consequently found to have an ovarian teratoma. The teratoma was removed and the patient remained asymptomatic with no relapses. The remaining six patients still suffer from ongoing behavioural, cognitive problems and seizures up to 5 years from initial presentation, and one child (Case 20) was intractable to all treatment. The median mRS score at nadir was 5 (range 2–5), and 2 (range 0–5) at 1-year follow-up. However, six patients continued to make progress postdischarge, despite limited or no ongoing treatment (figure 2B).

Early diagnosis (within 8 weeks)

Twenty children (65%) were diagnosed within 8 weeks of symptom onset, with a median time of 3 weeks from presentation to diagnosis (no patients were diagnosed between 8 weeks and 6 months). The clinical details are summarised in table 1B. The seven patients with partial phenotypes (Cases 8, 18, 19, 21, 23, 25, 29) were diagnosed 3 weeks later than the patients presenting with full NMDAR-Ab encephalitis phenotypes. At last follow-up (12–60 months), 78% (18/23) of patients with early diagnosis had made a full recovery with no sequelae and were rated an mRS score of 0 compared with the late diagnosed group where only one patient (Case 2) made a full eventual recovery (p=0.0011**, χ² for trend). The median mRS score at nadir was 4 (range 2–5), and 1 (range 0–4) at 1-year follow-up. Eight early diagnosed patients, seven with typical features of NMDAR-Ab encephalitis and one predominantly neuropsychiatric, made a full recovery within 12 months.
Five of these eight patients (63%), received PLEX as part of their initial treatment. Out of the four others who received PLEX, three also made a full recovery. Five of 23 (22%) patients had not made a full recovery with ongoing cognitive problems and learning difficulties, and one has refractory seizures requiring treatment with multiple anti-epileptic drugs (AEDs) (Case 15) (table 1A, B). Four out of these five received only steroids and IVIG as treatment.

Relapses
Seven patients (23%) had a clinical relapse, which was also confirmed by further antibody testing, (Cases 10, 14, 20, 23, 25, 28, 29); six out of seven relapsing patients (86%) had received steroids and IVIG only as their initial treatment. The median time to relapse from original presentation was 12.5 months (range: 2–60 months). The clinical presentation at the time of relapse was similar to acute but milder in severity. All relapses were treated with first-line immunotherapy with additional PLEX in one. Four of the seven (57%) patients went on to receive second-line or long-term immunotherapy at the time of relapse, with no further relapse, and full recovery in three patients. Only one patient had more than one relapse (Case 23).

DISCUSSION
NMDAR-Ab-associated neurological disorders are now well recognised in children who represent around 40% of the total number of cases.5–6 As most studies were done retrospectively on patients with well-defined NMDAR-Ab encephalitis,5–7 the incidence of this condition and the existence of less typical phenotypes has not been clear. In this prospective study, we gathered details on eight NMDAR-Ab-positive children presenting in the UK between November 2010 and December 2011, and an additional 23 who had already been identified as positive for serum NMDAR-Abs. From our data, we estimate the incidence to be 0.85/million children/year. The BPNSU relies on voluntary reporting by clinicians and, hence, could result in underestimation of the true incidence.

Our cohort had demographics similar to previously reported cohorts with female predominance and only 55% Caucasians.5–6 Only one girl had an ovarian teratoma. By contrast with a previously reported paediatric case series suggesting that children are more likely to present with a neurological rather than psychiatric phenotype,7–8 behavioural change and/or neuropsychiatric symptoms were reported in 90% of children. Nine patients (31%) presented under the age of 3 years confirming recent reports, and highlighting the importance of testing for NMDAR-Ab even in very young children.13

We did not identify a purely monosymptomatic group, but some patients (partial phenotypes) were not encephalopathic. These patients had additional associated features (particularly cognitive) in keeping with symptoms seen with NMDAR hypofunction. Although these were subtle, their identification was important in managing the patients appropriately and screening for the associated neoplasms. It remains unclear whether the treatment prevented these patients from developing full-blown encephalopathy, but the time from symptom onset to treatment in patients with partial phenotypes was longer than in patients presenting with NMDAR-Ab encephalitis. The psychiatric/movement disorder predominant disease was seen more frequently in male patients, in contrast with the overall female predominance. These phenotypical differences between the sexes were recently reported in an adult study14 suggesting that hormonal influences on the immune system or on target neurons, may contribute to the different clinical pictures.

The paraclinical features of our patients were similar to the previously reported series5–7 with normal MRI brain, encephalopathic EEG with or without epileptiform discharges, and CSF abnormalities in 45%. The pattern of extreme delta brush was not reported, although the neurophysiologists would not have looked for this at the time of the questionnaire completion.15 Positive viral serology was seen in two of the patients; the association between NMDAR-Ab encephalitis and some viruses, particularly herpes simplex virus (HSV) has previously been reported by us16 and others,17–19 with either co-occurrence at onset or HSV encephalitis triggering NMDAR-Ab encephalitis.

All patients received immunotherapy but with different regimes reflecting institutional or clinician preference. Most patients (78%) diagnosed and treated early made a full recovery compared with those diagnosed late (>6 months). There remains no controlled trial to provide high-quality evidence on the optimal therapeutic strategy for NMDAR-Ab encephalitis, nor is there the definitive distinction of what constitutes first-line and second-line therapy. A large cohort analysis5 appears to suggest the additional benefits of second-line therapy (rituximab, cyclophosphamide), when first-line therapy fails (steroids, IVIG and PLEX). Certainly, in the current study, the more symptomatic patients and those who relapsed were more likely to have their treatment escalated in this way. Although we did not find a difference in the long-term outcome between patients who received second-line immunotherapy or not, full recovery was seen in nearly all (8/9) patients receiving PLEX; this is higher than the group which only received steroids and immunoglobulin (p=0.049), and also higher than the reported literature.5–6 However, these data are confounded by early treatment and second-line immunotherapy in seven of the nine (78%) patients, in keeping with a recent report suggesting that the use of rituximab in paediatric neuroimmune conditions was associated with greater change in mRS in patients given rituximab early in their disease course compared with those treated later.20 A previous study in adults demonstrated a better cognitive outcome in patients treated early.21 Nevertheless, the response to treatment seen, even in the patients who were diagnosed late, support the role of any form of immunotherapy in all stages of active disease.

The average time of hospital stay in our cohort was 60 days, higher than in other forms of acquired encephalopathies,22 with 42% requiring admission to intensive care units. Appropriate management of these patients is challenging and frequently requires input of a multidisciplinary team. Speech and language therapists, physiotherapists and occupational therapists form the mainstay of this fundamental support team and should be engaged early in disease presentation for maximal benefit to the patients.

Taken together, careful use of treatment regimes and supportive therapies are essential to maximise patient care in this difficult-to-treat condition. Nevertheless, our study suggests that complete recovery can be achieved in the majority of paediatric NMDAR-Ab-mediated neurological diseases. Further studies of larger prospective cohorts and randomised treatment trials are still needed to establish the role of second-line immunotherapy and the duration of treatment needed for this condition.

Acknowledgements We would like to thank all the clinicians who provided their time to complete the questionnaires without which this study would not have been possible. Our thanks go to Drs/Professors Dulmini Birkett, Mary Callaghan, Antonia Clarke, Manali Chitre, Noma Dalalmini, Penny Fallon, Amanda Freeman, Katherine Forrest, Frances Gibbon, Tammy Hedderly, Cheryl Hemingway, Elaine Hughes, Anand Iyer, Tim Kerr, Fenella Kirkham, Rachel Kneen, Deepa Krishnakumar, Ram Kumar, Timothy Martland, Tony McShane, Nelly Ninis, Prab Prabahkar, Ramiah

Contributors The study was designed by SW, AV, EW, MS, SP, RG, SA with suggestions from YH and ML. LJ was responsible for antibody assays. SW collected and analysed data with assistance from YH. SW, YH, AV, EW and ML drafted and revised the manuscript; the remaining authors contributed revisions.

Funding This work was supported by a Wellcome Trust Clinical Research Training Fellowship (SW), Oxford University Clinical Academic Graduate School (YH), Birmingham Children’s Hospital Charitable Trust, the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and the University of Oxford (YH and AV).

Competing interests AV and the University of Oxford hold patents and receive royalties and payments for antibody assays.

Ethics approval Ethical approval for this study was from the Oxfordshire Regional Ethical Committee A (07/Q1604/28).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES

N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children

Sukhvir Wright, Yael Hacohen, Leslie Jacobson, Shakti Agrawal, Rajat Gupta, Sunny Philip, Martin Smith, Ming Lim, Evangeline Wassmer and Angela Vincent

Arch Dis Child published online January 30, 2015

Updated information and services can be found at:
http://adc.bmj.com/content/early/2015/01/30/archdischild-2014-306795

These include:

Supplementary Material
Supplementary material can be found at:
http://adc.bmj.com/content/suppl/2015/01/30/archdischild-2014-306795.DC1

References
This article cites 20 articles, 3 of which you can access for free at:
http://adc.bmj.com/content/early/2015/01/30/archdischild-2014-306795#BIBL

Open Access
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (206)
Infection (neurology) (287)
Child health (3922)
Immunology (including allergy) (2018)
Child and adolescent psychiatry (paediatrics) (683)
Epilepsy and seizures (391)
Memory disorders (psychiatry) (48)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/